Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 210 results:
Author [ Title] Type Year Filters: Author is Athyros, Vasilios G [Clear All Filters]
Mortality reduction in patients treated with intensive lipid therapy vs usual care. Re: Zhao XQ, Phan BA, Davis J et al. Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Tre.
J Clin Lipidol. 11(1), 306-307.
(2017). Multifactorial intervention for the prevention of vascular complications of type 2 diabetes..
Hellenic J Cardiol. 50(6), 445-8.
(2009). Nonalcoholic fatty liver disease and severity of cardiovascular disease manifestations..
Angiology. 64(8), 572-5.
(2013). Nonalcoholic fatty liver disease and statins..
Metabolism. 64(10), 1215-23.
(2015).
(2019).
(2014). Off target effects of statins shape total mortality?.
J Drug Assess. 5(1), 4-5.
(2016). Omega-3 fatty acids: how can they be used in secondary prevention?.
Curr Atheroscler Rep. 10(6), 510-7.
(2008). PCI and stable coronary heart disease--COURAGE to change our minds?.
Curr Vasc Pharmacol. 5(3), 173-4.
(2007). Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?.
J Clin Hypertens (Greenwich). 20(3), 469-471.
(2018). Peripheral artery disease in patients with type 2 diabetes..
J Diabetes Complications. 28(6), 912.
(2014). The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]..
Expert Opin Drug Metab Toxicol. 10(6), 787-812.
(2014). Pheochromocytoma: an update on genetics and management..
Endocr Relat Cancer. 14(4), 935-56.
(2007). Pleiotropic effects of statins--clinical evidence..
Curr Pharm Des. 15(5), 479-89.
(2009). The potential role of statins in treating liver disease..
Expert Rev Gastroenterol Hepatol. 12(4), 331-339.
(2018). Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit..
Expert Rev Cardiovasc Ther. 12(3), 295-6.
(2014). Prevalence and clinical outcome of polyvascular atherosclerotic disease in patients undergoing coronary intervention..
Circ J. 77(5), 1348.
(2013). Prevalence of vascular disease in metabolic syndrome using three proposed definitions..
Int J Cardiol. 117(2), 204-10.
(2007). Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?.
Open Cardiovasc Med J. 5, 226-30.
(2011). Preventing macrovascular complications of diabetes: where do we stand with glycemic control?.
Expert Opin Investig Drugs. 17(12), 1777-9.
(2008). Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes?.
Curr Pharm Des. 16(34), 3939-847.
(2010). Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?.
J Clin Hypertens (Greenwich). 20(5), 942-948.
(2018). Primary and secondary coronary heart disease prevention using statins: is targeting Adam or Eve equally effective?.
Expert Opin Pharmacother. 9(9), 1437-40.
(2008). Reaching hypertriglyceridemia goals..
Curr Med Res Opin. 30(3), 391-3.
(2014). Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?.
Open Cardiovasc Med J. 12, 29-40.
(2018).